Skip to content
developing-europe-header

DEVELOPING EUROPE & CIS

The main revenue contributor to our Developing Europe & CIS business is the Thrombosis Brands, followed by Regional Brands which are OTC and prescription.

Key Countries

The Czech Republic
Poland
Romania
Russia
Slovakia

developing-europe-csi
  • The Developing Europe & CIS Injectable thrombosis market was valued at EUR318 million as at March 2020.

Source: IQVIA – March 2020

STATISTICS

Number of products launched:

Nil

(2019: Nil)

Average staff turnover:

20%

(2019: 18%)

Number of product recalls:

Nil

(2019: Nil)

Number of work-related fatalities:

Nil

(2019: Nil)

Number of permanent employees

273

June 2020

264

June 2019

Revenue 2020
R’million
2019 (CER)
R’million
Change
%
Regional Brands 435 393 11
Sterile Focus Brands 2 116 2 289 (8)
Anaesthetics Brands 174 299 (42)
Thrombosis Brands 1 942 1 990 (2)
Total 2 551 2 682 (5)

Note: Commercial Pharmaceuticals revenue by customer geography.

Scroll To Top